Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

ALZpath Partners with Beckman Coulter Diagnostics to Develop Blood Test for Alzheimer's Disease Using Proprietary pTau217 Antibody

NextEdge Admin

15 Jul 2024

2 min 16 sec

ALZpath, Inc.has signed a licensing agreement with Beckman Coulter Diagnostics to utilize its innovative pTau217 antibody in a blood-based diagnostic test for Alzheimer's disease on the DxI 9000 Immunoassay Analyzer. This partnership aims to enhance Alzheimer’s disease diagnosis, addressing the urgent need for accurate and accessible testing as new treatments emerge.

The proprietary pTau217 antibody has demonstrated high diagnostic accuracy, sensitivity, and reliability in detecting Alzheimer’s disease, crucial for identifying patients eligible for clinical trials and emerging therapies. "Many individuals remain undiagnosed, impacting their access to necessary care," stated Chad Holland, CEO of ALZpath. Integrating this antibody into Beckman Coulter's platform will significantly expand access to precise testing and early diagnosis globally.

Blood-based assays using the pTau217 antibody show comparable accuracy to traditional diagnostic methods, such as PET imaging and cerebrospinal fluid testing, while offering the convenience and affordability of a simple blood test that can be performed in various clinical settings.

Kathleen Orland, senior vice president at Beckman Coulter, emphasized the importance of sensitive and scalable diagnostics for Alzheimer’s disease, noting that ALZpath's pTau217 antibody was selected for its outstanding performance in detecting amyloid pathology. This collaboration will lead to the development of a fully automated, high-throughput blood-based test for dementia patients worldwide.

The DxI 9000 Immunoassay Analyzer is a next-generation platform known for its high sensitivity and reliable throughput, making it well-suited for evolving healthcare demands.